Export

EN
FR
Linezolid
Essential medicine status
Section:
6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines
ATC codes: J01XX08
EMLc
Indication
Multi-drug resistant Mycobacterium tuberculosis ICD11 code: ML32.00
INN
Linezolid
Medicine type
Chemical agent
Antibiotic groups
RESERVE
List type
Core (EML)
(EMLc)
Additional notes
Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB contol.
Formulations
Oral > Solid > dispersible tablet: 150 mg (scored) (EMLc)
Oral > Solid > tablet: 600 mg
EML status history
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Changed in 2025 (TRS 1064)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Linezolid
DrugBank
Linezolid
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.